Predicting outcome of patients with myelodysplastic syndromes after failure of azacitidine: validation of the North American MDS consortium scoring system

相似書籍

• Outcome of patients with low-risk myelodysplasia after azacitidine treatment failure
  由: Thomas Prébet, et al.
  出版: (2013-02-01)
• Cost-effectiveness of azacitidine compared with low-doses of chemotherapy (LDC) in myelodysplastic syndrome (MDS)
  由: Myrna Candelaria-Hernández, et al.
  出版: (2017-06-01)
• Hematologic improvements in a myelodysplastic syndromes with myelofibrosis (MDS-F) patient treated with azacitidine
  由: Daisuke Okamura, et al.
  出版: (2014-01-01)
• PB2014: A PHASE 2/3 TRIAL OF ORAL AZACITIDINE IN PATIENTS WITH LOW- OR INTERMEDIATE-RISK MYELODYSPLASTIC SYNDROMES
  由: Guillermo Garcia-Manero, et al.
  出版: (2023-08-01)
• Toward a more patient‐centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)
  由: Fabio Efficace, et al.
  出版: (2024-05-01)